Eli Lilly and Co has patented a nasal drug delivery device with a method involving a medicament container, compressed gas container, and double-sided needle. By pressing an actuation button, the device expels powdered medicament through the outlet. The innovative design aims to improve drug delivery efficiency. GlobalData’s report on Eli Lilly and Co gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Eli Lilly and Co - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Eli Lilly and Co, Cancer treatment biomarkers was a key innovation area identified from patents. Eli Lilly and Co's grant share as of January 2024 was 54%. Grant share is based on the ratio of number of grants to total number of patents.

Patent granted for nasal drug delivery device

Source: United States Patent and Trademark Office (USPTO). Credit: Eli Lilly and Co

A recently granted patent (Publication Number: US11883588B2) discloses a method for operating a nasal drug delivery device. The method involves moving an actuation button to initiate the process, which includes piercing a medicament container containing powdered medication with a first needle and a compressed gas container with a second needle. This action opens a fluid flow communication between the two containers, allowing the powdered medication to be expelled from the medicament container through an outlet. The patent also describes a configuration where the first and second needles form a double-sided needle, with the fluid flow communication opening after both containers have been pierced.

Furthermore, the patent details additional features of the nasal drug delivery device, such as a needle hub attached to the double-sided needle, moveable biasing members positioned between the containers and the needle hub, and a specific arrangement of springs with different stiffness levels. The method also includes steps for piercing septums sealing the containers and specifies the use of powdered glucagon as the medicament. Another variation of the method involves moving the compressed gas container towards the second needle in response to the actuation button, ensuring the efficient expulsion of the powdered medication. Overall, the patent outlines a comprehensive method for operating a nasal drug delivery device, emphasizing the precise steps and components involved in the process.

To know more about GlobalData’s detailed insights on Eli Lilly and Co, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies